Phosphodiesterase Inhibitors Market

Phosphodiesterase Inhibitors Market Segmentation By Drug Class {Selective PDE Inhibitors (PDE-1, PDE-2, PDE-3, PDE-4, PDE-5 and Others) and Non-Selective PDE Inhibitors}; By Type (Oral, Typical and Others) and By Application (Respiratory Disease, Erectile Dysfunction, Vascular Disease, Diabetes and Others) – Global Demand Analysis & Opportunity Outlook 2028

Buy Now
Report ID: 2634 | Published On: Feb 01, 2022

Preview Analysis

Request Insights
Despite Inflation & Recession News, Businesses Across the Globe Expected to Do Better in 2023

In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.


In The News

  • Feb 24, 2017: Researchers from John Hopkin University reviewed the trials of PDE-5 inhibitors in pediatric patients with pulmonary hypertension. The researchers concluded that PDE-5 inhibitors can be safely prescribed to infants, neonates, and children with primary and secondary pulmonary hypertension





Get more information on this report: Request Sample PDF

Let Us Hear About Your Requirements:

Submit Your Request For Proposal (RFP)

Submit RFP    Buy Now Download Research Report Sample